(Q37863092)

24 August 2017

1 reference

title

Pharmacotherapy for smoking cessation: current advances and research topics (English)

1 reference

24 August 2017

0 references

Tobias Raupach

1 reference

24 August 2017

Constant P van Schayck

series ordinal

1 reference

24 August 2017

publication date

1 May 2011

1 reference

24 August 2017

1 reference

24 August 2017

1 reference

24 August 2017

1 reference

24 August 2017

page(s)

371-382

1 reference

Projections of global mortality and burden of disease from 2002 to 2030

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Update on pharmacologic options for smoking cessation treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Precessation treatment with nicotine patch significantly increases abstinence rates relative to conventional treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Nicotine gum treatment before smoking cessation: a randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Impact of over-the-counter sales on effectiveness of pharmaceutical aids for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Is nicotine replacement therapy for smoking cessation effective in the "real world"? Findings from a prospective multinational cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Discontinuation of nicotine replacement therapy among smoking-cessation attempters

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Adherence to nicotine replacement patch therapy in cardiovascular patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Relationship between adherence to daily nicotine patch use and treatment efficacy: secondary analysis of a 10-week randomized, double-blind, placebo-controlled clinical trial simulating over-the-counter use in adult smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Increasing the use of nicotine replacement therapy by a simple intervention: an exploratory trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Understanding why smokers do not want to use nicotine dependence medications to stop smoking: qualitative and quantitative studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

A randomized controlled trial to assess the effects of reimbursing the costs of smoking cessation therapy on sustained abstinence

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Reimbursement for smoking cessation treatment may double the abstinence rate: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Effect of Medicaid coverage of tobacco-dependence treatments on smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Medicaid reimbursement for prenatal smoking intervention influences quitting and cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Influence of smoking cessation after diagnosis of early stage lung cancer on prognosis: systematic review of observational studies with meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Mechanisms of smoking-related lung and pancreatic adenocarcinoma development

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Signalling pathways involved in nicotine regulation of apoptosis of human lung cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Nicotine promotes tumor growth and metastasis in mouse models of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Does nicotine replacement therapy cause cancer? Evidence from the Lung Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Is the inhibition of nicotinic acetylcholine receptors by bupropion involved in its clinical actions?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Behavioural and pharmacological mechanisms of bupropion's anti-smoking effects: recent preclinical and clinical insights

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

The cost-effectiveness of antidepressants for smoking cessation in chronic obstructive pulmonary disease (COPD) patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Bupropion and cognitive behavioral therapy for weight-concerned women smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Beliefs and attitudes about bupropion: implications for medication adherence and smoking cessation treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Effect of varenicline and bupropion SR on craving, nicotine withdrawal symptoms, and rewarding effects of smoking during a quit attempt

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation--results from four European countries

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Cost-effectiveness of varenicline for smoking cessation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Evaluation of varenicline as an aid to smoking cessation in UK general practice - a THIN database study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Varenicline in prevention of relapse to smoking: effect of quit pattern on response to extended treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Do the 10 UK suicides among those taking the smoking cessation drug varenicline suggest a causal link?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Psychiatric adverse events in randomized, double-blind, placebo-controlled clinical trials of varenicline: a pooled analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Tobacco dependence and withdrawal: science base, challenges and opportunities for pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Translational research in medication development for nicotine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Gabapentin for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

A double-blind, placebo-controlled, randomized clinical trial of oral selegiline hydrochloride for smoking cessation in nicotine-dependent cigarette smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

The GABA B agonist baclofen reduces cigarette consumption in a preliminary double-blind placebo-controlled smoking reduction study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Olanzapine reduces urge to smoke and nicotine withdrawal symptoms in community smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Neural mechanisms underlying nicotine dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Nicotinic receptor-based therapeutics and candidates for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Characterization of nicotinic agonist-induced [(3)H]dopamine release from synaptosomes prepared from four mouse brain regions

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

An uncontrolled trial of cytisine (Tabex) for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Sazetidine-A is a potent and selective agonist at native and recombinant alpha 4 beta 2 nicotinic acetylcholine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Negative allosteric modulation of nicotinic acetylcholine receptors blocks nicotine self-administration in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Effect of a novel nicotinic receptor antagonist, N,N'-dodecane-1,12-diyl-bis-3-picolinium dibromide, on nicotine self-administration and hyperactivity in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Role of the glutamatergic system in nicotine dependence : implications for the discovery and development of new pharmacological smoking cessation therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Trial comes too late as psychiatric side effects end hope for rimonabant

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Vaccines against nicotine

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Nicotine hapten structure, antibody selectivity and effect relationships: results from a nicotine vaccine screening procedure

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Nicotine vaccines: will smokers take a shot at quitting?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

The immunogenicity and safety of a nicotine vaccine in smokers and nonsmokers: results of a randomized, placebo-controlled phase 1/2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

A vaccine against nicotine for smoking cessation: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Combination pharmacotherapy for stopping smoking: what advantages does it offer?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Nicotine nasal spray with nicotine patch for smoking cessation: randomised trial with six year follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Comparative effectiveness of 5 smoking cessation pharmacotherapies in primary care clinics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Triple-combination pharmacotherapy for medically ill smokers: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

A randomized trial of nortriptyline combined with transdermal nicotine for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Nortriptyline plus nicotine replacement versus placebo plus nicotine replacement for smoking cessation: pragmatic randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Combination treatment with varenicline and nicotine replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Varenicline and bupropion sustained-release combination therapy for smoking cessation

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: follow-up of a randomised clinical trial of transdermal nicotine patch

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Cross-validation of a new procedure for early screening of smoking cessation medications in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Development of procedures for early screening of smoking cessation medications in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Disparities in tobacco cessation medication orders and fills among special populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Smoking cessation interventions offered to French adult light smokers: a heterogeneous population with specific needs

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Physical activity as an aid to smoking cessation during pregnancy: two feasibility studies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Bupropion SR and counseling for smoking cessation in actual practice: predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Meta-analysis of the efficacy of nicotine replacement therapy for smoking cessation: differences between men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Employment, gender, and smoking cessation outcomes in low-income smokers using nicotine replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Explaining the social gradient in smoking cessation: it's not in the trying, but in the succeeding

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Social inequalities in male mortality, and in male mortality from smoking: indirect estimation from national death rates in England and Wales, Poland, and North America

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Citations to trials of nicotine replacement therapy were biased toward positive results and high-impact-factor journals

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Over-the-counter nicotine replacement therapy: a methodological review of the evidence supporting its effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Do implementation issues influence the effectiveness of medications? The case of nicotine replacement therapy and bupropion in UK Stop Smoking Services

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

A smoking ban in public places increases the efficacy of bupropion and counseling on cessation outcomes at 1 year.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Patient costs as a barrier to intensive health behavior counseling

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

The global research neglect of unassisted smoking cessation: causes and consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

"Catastrophic" pathways to smoking cessation: findings from national survey

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Cost effectiveness of varenicline in Belgium, compared with bupropion, nicotine replacement therapy, brief counselling and unaided smoking cessation: a BENESCO Markov cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Increasing the demand for and use of effective smoking-cessation treatments reaping the full health benefits of tobacco-control science and policy gains--in our lifetime

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Chronic obstructive pulmonary disease: are women more susceptible than men?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Women's susceptibility to tobacco carcinogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11590620-000000000-00000

Encouraging smokers to quit: the cost effectiveness of reimbursing the costs of smoking cessation treatment

21 January 2018

1 reference

12 December 2020

Interventions for preventing weight gain after smoking cessation

1 reference

12 December 2020

Comparative testing of 5 nicotine systems: initial use and preferences.

1 reference

12 December 2020

Physician advice for smoking cessation

1 reference

12 December 2020

CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions.

1 reference

12 December 2020

Nicotine inhaler and nicotine patch as a combination therapy for smoking cessation: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Methods used to quit smoking in the United States. Do cessation programs help?

1 reference

12 December 2020

Pharmacogenetics of smoking cessation therapy.

1 reference

12 December 2020

Nicotine replacement therapy for smoking cessation

1 reference

12 December 2020

Nicotine receptor partial agonists for smoking cessation

1 reference

12 December 2020

10.2165/11590620-000000000-00000

Identifiers

DOI

1 reference

24 August 2017

1 reference